| | SLO | ENG | Piškotki in zasebnost

Večja pisava | Manjša pisava

Izpis gradiva Pomoč

Naslov:Commercial SARS-CoV-2 targeted, protease inhibitor focused and protein–protein interaction inhibitor focused molecular libraries for virtual screening and drug design
Avtorji:ID Kralj, Sebastjan (Avtor)
ID Jukič, Marko (Avtor)
ID Bren, Urban (Avtor)
Datoteke:.pdf ijms-23-00393.pdf (6,53 MB)
MD5: E8B2EFB155CEA0F69918D87FB880CB9D
 
URL https://www.mdpi.com/1422-0067/23/1/393
 
Jezik:Angleški jezik
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:FKKT - Fakulteta za kemijo in kemijsko tehnologijo
FNM - Fakulteta za naravoslovje in matematiko
Opis:Since December 2019, the new SARS-CoV-2-related COVID-19 disease has caused a global pandemic and shut down the public life worldwide. Several proteins have emerged as potential therapeutic targets for drug development, and we sought out to review the commercially available and marketed SARS-CoV-2-targeted libraries ready for high-throughput virtual screening (HTVS). We evaluated the SARS-CoV-2-targeted, protease-inhibitor-focused and protein–protein-interactioninhibitor-focused libraries to gain a better understanding of how these libraries were designed. The most common were ligand- and structure-based approaches, along with various filtering steps, using molecular descriptors. Often, these methods were combined to obtain the final library. We recognized the abundance of targeted libraries offered and complimented by the inclusion of analytical data; however, serious concerns had to be raised. Namely, vendors lack the information on the library design and the references to the primary literature. Few references to active compounds were also provided when using the ligand-based design and usually only protein classes or a general panel of targets were listed, along with a general reference to the methods, such as molecular docking for the structure-based design. No receptor data, docking protocols or even references to the applied molecular docking software (or other HTVS software), and no pharmacophore or filter design details were given. No detailed functional group or chemical space analyses were reported, and no specific orientation of the libraries toward the design of covalent or noncovalent inhibitors could be observed. All libraries contained pan-assay interference compounds (PAINS), rapid elimination of swill compounds (REOS) and aggregators, as well as focused on the drug-like model, with the majority of compounds possessing their molecular mass around 500 g/mol. These facts do not bode well for the use of the reviewed libraries in drug design and lend themselves to commercial drug companies to focus on and improve.
Ključne besede:targeted libraries, focused libraries, computer-aided drug design, virtual screening, in silico drug design, high-throughput virtual screening
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Poslano v recenzijo:07.12.2021
Datum sprejetja članka:28.12.2021
Datum objave:30.12.2021
Založnik:MDPI
Leto izida:2022
Št. strani:22 str.
Številčenje:Vol. 23, no. 1
PID:20.500.12556/DKUM-92444 Novo okno
UDK:577
COBISS.SI-ID:92031235 Novo okno
DOI:10.3390/ijms23010393 Novo okno
ISSN pri članku:1422-0067
Avtorske pravice:© 2021 by the authors
Datum objave v DKUM:09.04.2025
Število ogledov:181
Število prenosov:11
Metapodatki:XML DC-XML DC-RDF
Področja:Ostalo
:
Kopiraj citat
  
Skupna ocena:(0 glasov)
Vaša ocena:Ocenjevanje je dovoljeno samo prijavljenim uporabnikom.
Objavi na:Bookmark and Share



Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:International journal of molecular sciences
Skrajšan naslov:Int. j. mol. sci.
Založnik:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P2-0046-2019
Naslov:Separacijski procesi in produktna tehnika

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:J1-2471-2020
Naslov:Kemijska karcinogeneza: Mehanistični vpogled

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:J1-1715-2019
Naslov:Atlas proteinskih interakcij za napovedovanje genskih variacij povezanih z interakcijami z zdravili in razvojem bolezni

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:N1-0209-2021
Naslov:Orodja za inovativno oblikovanje zdravil

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:J1-9186-2018
Naslov:Razvoj novih računskih orodij na PDB ravni za odkrivanje zdravil

Financer:the Slovenian Ministry of Science and Education
Program financ.:infrastructure project grant
Akronim:HPC-RIVR

Financer:the Slovenian Ministry of Science and Education
Program financ.:infrastructure project grant
Akronim:RI-SI-ELIXIR

Financer:the Slovenian Ministry of Education, Science and Sports
Program financ.:program grant
Številka projekta:OP20.04342

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:inhibitorji proteaze, zdravila, proteini


Komentarji

Dodaj komentar

Za komentiranje se morate prijaviti.

Komentarji (0)
0 - 0 / 0
 
Ni komentarjev!

Nazaj
Logotipi partnerjev Univerza v Mariboru Univerza v Ljubljani Univerza na Primorskem Univerza v Novi Gorici